Cardiff Oncology to Report Third Quarter 2023 Financial Results and Provide Business Update

Rhea-AI Summary

Cardiff Oncology plans to release financial results for the third quarter on November 2 and will hold a conference call and webcast on the same day.

Positive

• Investors can listen to the live conference call and webcast to gain insights into the company's financial performance and future prospects.

Negative

• No negative takes found.

- Management will hold a conference call on Thursday, November 2 at 4:30 p.m. ET/1:30 p.m. PT -

SAN DIEGO, Oct. 26, 2023 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that it plans to release financial results for the third quarter ended September 30, 2023 on Thursday, November 2 after the close of trading.

Conference Call and Webcast

Cardiff Oncology will host a conference call and live webcast at 4:30 p.m. ET/1:30 p.m. PT on November, 2 2023. Individuals interested in listening to the live conference call may do so by using the webcast link in the "Investors" section of the company's website at https://cardiffoncology.investorroom.com/events. A replay will be available in the investor relations section on the company's website following the completion of the call.

About Cardiff Oncology, Inc.

Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers. The Company's lead asset is onvansertib, a PLK1 inhibitor being evaluated in combination with standard-of-care (SoC) therapeutics in clinical programs targeting indications such as RAS-mutated metastatic colorectal cancer (mCRC) and metastatic pancreatic ductal adenocarcinoma (mPDAC), as well as in investigator-initiated trials in small cell lung cancer (SCLC) and triple negative breast cancer (TNBC). These programs and the Company's broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SoC alone. For more information, please visit https://www.cardiffoncology.com.

Cardiff Oncology Contact:
James Levine
Chief Financial Officer
858-952-7670
jlevine@cardiffoncology.com

Investor Contact:
Kiki Patel, PharmD
Gilmartin Group
332-895-3225
Kiki@gilmartinir.com

Media Contact:
Richa Kumari
Taft Communications
551-344-5592
richa@taftcommunications.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/cardiff-oncology-to-report-third-quarter-2023-financial-results-and-provide-business-update-301969276.html

SOURCE Cardiff Oncology, Inc.

FAQ

When will Cardiff Oncology release its financial results for the third quarter?

Cardiff Oncology plans to release its financial results for the third quarter on November 2.

What time will the conference call and webcast take place?

The conference call and webcast will take place at 4:30 p.m. ET/1:30 p.m. PT on November 2.

Where can investors listen to the live conference call and webcast?

Investors can listen to the live conference call and webcast by visiting the 'Investors' section of Cardiff Oncology's website at https://cardiffoncology.investorroom.com/events.

Will there be a replay available after the conference call?

Yes, a replay will be available in the investor relations section on Cardiff Oncology's website following the completion of the call.